5 Biotech Stocks to Buy According to Matthew Strobeck's Birchview Capital
In this article, we discuss 5 biotech stocks to buy according to Matthew Strobeck's Birchview Capital.
Foghorn Therapeutics Inc. (FHTX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 5,842,000 | $28,508,960 | 0.73% | |
| 2. | Deerfield Management James E. Flynn | 4,394,367 | $21,444,511 | 0.22% | |
| 3. | Euclidean Capital Jim Simons | 1,573,761 | $7,679,954 | 1.75% | |
| 4. | Siren L.L.C. Raymond Debbane | 720,720 | $3,517,114 | 0.07% | |
| 5. | Renaissance Technologies Jim Simons | 377,936 | $1,844,328 | -8% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.00 | 5,500 | $88,000.00 | 258,397 | 2020-10-27 | Filing | |
| $16.00 | 50,000 | $800,000.00 | 1,851,801 | 2020-10-27 | Filing | |
| $16.00 | 50,000 | $800,000.00 | 1,491,441 | 2020-10-27 | Filing | |
| $16.00 | 50,000 | $800,000.00 | 9,330,878 | 2020-10-27 | Filing | |
| $16.00 | 150,000 | $2,400,000.00 | 1,231,081 | 2020-10-27 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.17 | 857 | $8,715.69 | 0 | 2024-09-23 | Filing | |
| $10.04 | 35,756 | $358,990.24 | 0 | 2024-09-20 | Filing | |
| $10.05 | 11,574 | $116,318.70 | 0 | 2024-09-18 | Filing | |
| $10.04 | 10,272 | $103,130.88 | 0 | 2024-09-17 | Filing | |
| $10.00 | 400 | $4,000.00 | 0 | 2024-09-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,674,120 | $61,849,706 | 4.02% | |
| 2. | 5,705,958 | $27,845,075 | 0% | |
| 3. | 2,626,832 | $12,818,939 | 0% | |
| 4. | 2,489,978 | $12,151,093 | 0% | |
| 5. | 1,494,611 | $7,293,702 | 0% |
News See All
5 Best Biotech and AI Stocks To Buy According To Billionaire Jim Simons
In this article, we discuss 5 stock picks of Jim Simons’ Euclidean Capital.
10 Pharmaceutical Stocks to Buy According to Jim Simons’ Euclidean Capital
In this article, we reviewed Jim Simons' investment strategy, historical performance, and family office portfolio.
11 Best Pharma and Biotech Stocks to Buy According to Jim Simons' Euclidean Capital
Jim Simons is the President of Euclidean Capital, a family office.